Vaccine

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.

What are Vaccines?

There are several diseases like Diphtheria, whooping cough (pertussis), measles, mumps, Yellow fever, small pox and German measles (rubella) that are unfamiliar to many these days.

Vaccine History

What is a Vaccine Breakthrough?

What are the Main Causes of Vaccine Hesitancy?

Investigating the Importance of Investing in Vaccine Manufacturing

Vaccine Schedule

Vaccine Effectiveness

Vaccination in Humanitarian Settings

Plant-Derived Vaccines

Vaccine Production

Vaccine Excipients

Vaccine Delivery

See more featured articles »

Vaccine Immunity

Hib Immunization

History of Vaccination

How are Vaccines Stored?

What are the Different Types of Vaccines?

What is a Subunit Vaccine?

What is an Inactivated Vaccine?

What is a Live-Attenuated Vaccine?

What is a Toxoid Vaccine?

What is an RNA Vaccine?

What is a DNA Vaccine?

What are Adenovirus-Based Vaccines?

What is a Non-Replicating Vaccine?

What is a VLP Vaccine?

What are Nanoparticle-Based Vaccines?

The Future of Vaccines

Insight into Personalized Vaccines

Could there be a Salmonella Vaccine?

Role of Computer Modeling in Vaccine Development

How Veterinary Vaccines Affect Human Health

A New Breed of Vaccine: Exploring Doggybone ™ DNA Technology

What is the Importance of Vaccination Coverage?

The Big Catch-Up: How the COVID-19 pandemic impacted vaccination coverage

Transforming Vaccine Design: The Promise of Systems Biology

What is Immunobridging?

Immunization strategies: What lessons can we learn from successful campaigns?

The Essential Program on Immunization is 50: Milestones, achievements, and future directions

Latest Vaccine News and Research

Cognitive distortions and deliberate ignorance lead to COVID-19 vaccine refusal, study says

Researchers find that deliberate ignorance and cognitive distortions drive COVID-19 vaccine refusal, emphasizing the need for tailored communication strategies.

17 Sep 2024

Single dose of MVA-BN vaccine offers 58% protection against mpox

Researchers confirm the effectiveness of the modified vaccinia Ankara-Bavarian Nordic vaccine against mpox.

16 Sep 2024

New research network focuses on high-priority viruses

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises-;both in the United States and around the world. NIH's National Institute of Allergy and Infectious Diseases (NIAID) expects to commit approximately $100 million per year to fund the program, pending the availability of funds.

14 Sep 2024

Evolution of vaccine adjuvants from empirical discovery to rational design

Vaccine adjuvants have evolved significantly since their inception, transitioning from empirical discovery to a more structured approach grounded in rational drug design.

13 Sep 2024

National survey reveals vaccine hesitancy ahead of flu and COVID-19 season

With flu season just around the corner and COVID-19 cases on the rise, a new nationwide survey from The Ohio State University Wexner Medical Center reveals hesitancy around vaccines this fall.

13 Sep 2024

New mechanism aims to ensure equitable distribution of mpox vaccines and treatments

In coordination with Member States, the World Health Organization (WHO) and partners have established an access and allocation mechanism for mpox medical countermeasures including vaccines, treatments and diagnostic tests.

13 Sep 2024

WHO adds MVA-BN vaccine to prequalification list as first vaccine against mpox

The World Health Organization (WHO) has announced the MVA-BN vaccine as the first vaccine against mpox to be added to its prequalification list.

13 Sep 2024

COVID-19 vaccines prevented millions of deaths across Latin America and the Caribbean, study shows

Researchers estimate that COVID-19 vaccines averted between 610,000 and 2.62 million deaths in select Latin American and Caribbean countries from early 2021 to May 2022.

12 Sep 2024

New vaccine candidate shows promise for protecting against Lassa fever

Researchers from Thomas Jefferson University and the University of Maryland Baltimore, in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation, have developed a promising new vaccine candidate that protects against Lassa fever.

12 Sep 2024

Single dose of MVA-BN vaccine shows 58% effectiveness against mpox

A single dose of the Modified vaccinia Ankara-Bavarian Nordic (MVA-BN) was 58% effective in protecting again mpox infection, according to a new study published in BMJ.

11 Sep 2024

COVID-19 mRNA vaccine linked to myocardial scarring in adolescents and young adults

The study investigates COVID-19 vaccine-related myocarditis in adolescents, revealing clinical characteristics and risks of myocardial injury in young adults.

11 Sep 2024

Obesity increases risk of contracting COVID-19 after exposure to SARS-CoV-2

Researchers reveal that obesity also increases the risk of contracting COVID-19 following exposure to SARS-CoV-2.

11 Sep 2024

Study reveals population-wide immune setpoint for SARS-CoV-2 antibodies

Researchers discovered that SARS-CoV-2 antibody levels in the Dominican Republic converge to a population-wide immune setpoint, regardless of individual vaccination or infection history.

10 Sep 2024

Targeted RSV vaccination for older adults with health conditions found cost-effective

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study https://www.cmaj.ca/lookup/doi/10.1503/cmaj.240452 in CMAJ.

9 Sep 2024